Navigation Links
New compound overcomes drug-resistant Staph infection in mice
Date:1/7/2013

CHAMPAIGN, lll. Researchers have discovered a new compound that restores the health of mice infected with methicillin-resistant Staphylococcus aureus (MRSA), an otherwise dangerous bacterial infection. The new compound targets an enzyme not found in human cells but which is essential to bacterial survival.

The research team, led by scientists at the University of Illinois and the University of California, San Diego, reports the new findings in the Proceedings of the National Academy of Sciences. The team discovered and developed several compounds that are promising leads for antibacterial drug development, and the most potent was tested in mice infected with MRSA.

The rise of antibiotic-resistant bacterial infections is a global public health problem, said U. of I. chemistry professor Eric Oldfield, who led the research with UC San Diego professor Andrew McCammon.

"There's an urgent need for more antibiotics because of drug resistance," Oldfield said. "There are, for example, completely drug-resistant strains of tuberculosis. None of the drugs work against these strains of tuberculosis and so, if you get it, you die."

Other infections, such as gonorrhea, which once were easily cured with antibiotics, also are becoming resistant to treatment, Oldfield said. "And Staph itself actually kills more people in the U.S. than does HIV/AIDS."

To begin the study, McCammon and his colleagues at UC San Diego used computer simulations to look for potential chinks in the armor of a bacterial enzyme known as FPPS that aids in bacterial cell wall formation. The researchers then screened libraries of small molecules to identify some that might target those sites and interrupt the activity of FPPS. Oldfield's team tested some of these molecules against FPPS, but found that they were not particularly potent inhibitors of the enzyme.

"Then we tested the most promising compound against the next enzyme in the pathway, and we found that it was 20 times more active against that enzyme," Oldfield said.

That enzyme, called UPPS, "is important because it's involved in bacterial cell wall biosynthesis," he said. "And a lot of the antibiotics that we have drugs like penicillin, methicillin, vancomycin all target bacterial cell wall biosynthesis."

Graduate student Wei Zhu and research scientist Yonghui Zhang worked with Oldfield to develop and test new analogs of the compound that worked against UPPS.

"And we found one that was about 1,000 times more active than the first hit we had against FPPS," Oldfield said.

Illinois chemistry and Institute for Genomic Biology professor Douglas Mitchell tested the new compound against regular and drug-resistant S. aureus in cell culture and found that it had potent activity against both.

"He also found that it augmented the effects of methicillin" in methicillin-resistant Staph strains, Oldfield said.

In a final test, Dr. Victor Nizet at UC San Diego used the new compound to treat mice infected with MRSA.

"Twenty out of 20 animals survived if they were treated with this drug lead and zero survived if they weren't treated," Oldfield said.

More years of study will be needed to determine whether this compound or others like it will be effective in humans, Oldfield said, but the findings may allow scientists to target multiple enzymes essential to bacterial survival, thus reducing the likelihood that new forms of drug resistance will emerge.


'/>"/>

Contact: Diana Yates
diya@illinois.edu
217-333-5802
University of Illinois at Urbana-Champaign
Source:Eurekalert  

Related biology news :

1. Canadian girl, 16, invents disease-fighting, anti-aging compound using tree particles
2. Biosensor illuminates compounds to aid fight against TB
3. New screening technique yields elusive compounds to block immune-regulating enzyme
4. Sulphur and iron compounds common in old shipwrecks
5. Heparin-like compounds inhibit breast cancer metastasis to bone
6. Like curry? New biological role identified for compound used in ancient medicine
7. Nuisance seaweed found to produce compounds with biomedical potential
8. Dont feel like exercise? Scientists find compound that may help you work out harder
9. New drug-screening method yields long-sought anti-HIV compounds
10. Nonstoichiometric Compounds V - An ECI Conference Series
11. New compound holds promise for treating Duchenne MD, other inherited diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New compound overcomes drug-resistant Staph infection in mice
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... 20, 2017  Eli Lilly and Company (NYSE: ... galcanezumab for the prevention of migraine at the American ... place April 22-28, 2017, in Boston ... at AAN, including safety and patient outcomes data for ... a reduction in monthly migraine headache days among patients ...
(Date:4/20/2017)... ... 20, 2017 , ... NetDimensions appoints Bill Mastin, a learning technology veteran, as ... experience in the learning technologies industry, Mastin joins NetDimensions from the New York office ... (LTG). At LEO, Mastin served as SVP of the North America offices and prior ...
(Date:4/20/2017)... ... April 20, 2017 , ... Parallel6™ , the leader ... announced today that they were named one of the 2017 Top 10 eClinical ... developments in the pharmaceutical industry. , “We take pride in honoring Parallel6 as one ...
(Date:4/20/2017)... HACKENSACK, N.J. and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell technologies ... Chief Executive Officer, will present at the Alliance for Regenerative ... Investor Day on Thursday, April 27, 2017 at 09:40 EDT ... Dr. Ralph Kern , MD, MHSc, Chief Medical Officer ...
Breaking Biology Technology: